Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study

被引:20
|
作者
Wu, Simon [1 ,2 ]
Chee, Desmond [1 ,2 ]
Ugalde, Anna [1 ,3 ]
Butow, Phyllis [4 ]
Seymour, John [2 ,5 ]
Schofield, Penelope [1 ,2 ,6 ]
机构
[1] Peter MacCallum Canc Ctr, Dept Canc Experiences Res, East Melbourne, Vic, Australia
[2] Univ Melbourne, Fac Med Dent & Hlth Sci, Parkville, Vic 3052, Australia
[3] St Vincents Hosp Melbourne, Ctr Palliat Care, Fitzroy, Vic, Australia
[4] Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia
[5] Peter MacCallum Canc Ctr, Dept Hematol, East Melbourne, Vic, Australia
[6] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia
基金
英国医学研究理事会;
关键词
Cancer; Adherence; Chronic myeloid leukemia; Qualitative; Imatinib; DOWNWARD EVALUATION; FOLLOW-UP; COMPLEMENTARY; MEDICINE; CANCER; INTERVENTIONS; ONCOLOGISTS; REGIMENS; BEHAVIOR;
D O I
10.1017/S1478951513001260
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: Consistent use of imatinib is critical for treatment success in chronic myeloid leukemia, yet perfect adherence to the prescribed clinical regimen is reported to be as low as 14%. This study aimed to understand patients' experiences of chronic myeloid leukemia with a qualitative approach, including identified facilitators and barriers to adherence, drawing on patients' and health professionals' perspectives, recording comments made by patients and health professionals involved with the same treatment team. Method: We recruited patients with chronic myeloid leukemia prescribed imatinib therapy and health professionals involved in their treatment from a specialized cancer center. Semi-structured qualitative interviews were recorded, transcribed, and manually analyzed using interpretive phenomenological analysis. Recruitment ceased upon saturation, with 16 patients and 10 health professionals (hematologists n = 4, nurses n = 3, pharmacists n = 3). Results: Twelve patients reported at least one instance of nonadherence. Reasons for unintentional nonadherence included forgetfulness related to variations of routine and doctor-patient communication issues. Reasons for intentional nonadherence included desires to reduce dose-dependent side effects and insufficient support. Patients who reported higher nonadherence rates felt complacent following periods of sustained disease control or had received conflicting advice regarding nonadherence. Health professionals had difficulty in accurately evaluating medication adherence due to a lack of reliable measures, utilizing patient self-report and manifestations of suboptimal disease control to guide assessments. Significance of Results: Adherence issues persist throughout the course of treatment. While high patient-reported nonadherence rates were recorded, health professionals were often unaware of the complex causes, compounded by an inadequacy of adherence assessment tools. Some patients reported nonadherence events because of insufficient education or lack of access to prompt medical guidance. These issues should be addressed to improve clinical practice.
引用
收藏
页码:255 / 263
页数:9
相关论文
共 50 条
  • [41] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Abbott, Brian L.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 272 - 281
  • [42] Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy
    Aduwa, Elvis
    Szydlo, Richard
    Marin, David
    Foroni, Letizia
    Reid, Alistair
    Goldman, John
    Apperley, Jane F.
    Milojkovic, Dragana
    BLOOD, 2012, 120 (25) : 5087 - 5088
  • [43] Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
    Swords, Ronan
    Mahalingam, Devalingam
    Padmanabhan, Swaminathan
    Carew, Jennifer
    Giles, Francis
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2009, 3 : 89 - 101
  • [44] Outcome of patients with chronic myeloid leukemia who recieved an intermittent imatinib therapy
    Goh, Hyun-Gyung
    Kim, Soo-Hyun
    Lee, Jeong
    Jang, Sae-Eun
    Kim, Wan-Seok
    Kim, Yoo-Li
    Park, Sa-Hee
    Kwon, Il-Young
    Kim, Dong-Wook
    BLOOD, 2007, 110 (11) : 313A - 313A
  • [45] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia
    Clark, Richard E.
    Davies, Andrea
    Pirmohamed, Munir
    Giannoudis, Athina
    LEUKEMIA & LYMPHOMA, 2008, 49 (04) : 639 - 642
  • [46] Weight gain associated with imatinib therapy in patients with chronic myeloid leukemia (CML).
    Ault, P
    Kantarjian, H
    Kaled, S
    Rios, MB
    O'Brien, S
    Cortes, JE
    BLOOD, 2002, 100 (11) : 321B - 321B
  • [47] DASATINIB TREATMENT OF IMATINIB-RESISTANT AND IMATINIB-INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN A CHRONIC PHASE
    Vinogradova, O. Yu.
    Turkina, A. G.
    Vorontsova, A. V.
    Chelysheva, E. Yu.
    Gusarova, G. A.
    Kuznetsov, S. V.
    Goryacheva, S. R.
    Sokolova, M. A.
    Abakumov, E. M.
    Stakhina, O. V.
    Domracheva, E. V.
    Misyurin, A. V.
    Khoroshko, N. D.
    TERAPEVTICHESKII ARKHIV, 2009, 81 (07) : 41 - 46
  • [48] Assessment of Imatinib as a Primary Treatment of Chronic Myeloid Leukemia in Chronic Phase: a Cohort Study
    Merin, Dana
    Krishna, Akshaya
    Jayakumar, Sreelekshmi
    Mahima, A.
    Anila, K. N.
    Sidharthan, Neeraj
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (03) : 547 - 556
  • [49] Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response
    Agirre, X
    Fontalba, A
    Andreu, EJ
    Odero, MD
    Larróyoz, MJ
    Montiel, C
    Calasanz, M
    Fernández-Luna, JL
    Prósper, F
    HAEMATOLOGICA, 2003, 88 (12) : 1425 - 1426
  • [50] Comment on "Effect of imatinib treatment on renal anemia in chronic myeloid leukemia patients"
    Ansari, Ramin
    Taghizadeh-Ghehi, Maryam
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (08) : 2057 - 2058